Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Thyrotropin-Releasing Hormone as a Pituitary-Function Indicator: A Comparison With Other Tests

Thyrotropin-Releasing Hormone as a Pituitary-Function Indicator: A Comparison With Other Tests Abstract Pituitary thyrotropin reserves were tested with intravenous injections of 500μg of lopremone (synthetic thyrotropin-releasing hormone) in eight normal subjects, ten patients with complete hypopituitarism, and ten with incomplete hypopituitarism. Normal subjects had a mean basal thyrotropin-stimulating hormone level of 2.3μ± 1.8μU/ml and attained a mean maximal thyrotropin-stimulating hormone level of 19.8μ ± 8.2μU/ml 20 to 30 minutes after injection; no marked response occurred in patients with complete hypopituitarism. Of the incomplete hypopituitarism group, two had subnormal responses and were clinically hypothyroid. The others, clinically euthyroid, had normal responses compared to normal subjects of similar ages. Growth hormone reserve in this group was first to show impairment, whereas adrenocorticotropic hormone and thyrotropin-stimulating hormone reserves were last affected. The lopremone stimulation test is useful and specific in evaluating pituitary thyrotropin reserve. References 1. Hershman JM, Pittman JA Jr: Response to synthetic thyrotropin-releasing hormone in man. J Clin Endocrinol Metab 31:457-460, 1970.Crossref 2. Ormston BJ, et al: Further observations on the effect of synthetic thyrotropin-releasing hormone in man. Br Med J 2:199-202, 1971.Crossref 3. Anderson MS, et al: Synthetic thyrotropin-releasing hormone: A potent stimulator of thyrotropin secretion in man. N Engl J Med 285:1279-1283,1971.Crossref 4. Bowers CY, et al: Prolactin and thyrotropin release in man by synthetic pyroglutamyl-histidyl-prolinamide. Biochem Biophys Res Commun 45:1033-1041, 1971.Crossref 5. Fleisher N, et al: Preliminary observations on the effect of synthetic thyrotropin-releasing factor on plasma thyrotropin levels in man. J Clin Endocrinol Metab 31:109-112, 1970.Crossref 6. Haigler ED Jr, et al: Direct evaluation of pituitary thyrotropin releasing hormone. J Clin Endocrinol Metab 33:573-581, 1971.Crossref 7. Costom BH, Grumbach MM, Kaplan SL: Effect of thyrotropin-releasing factor on serum thyroid-stimulating hormone: An approach to distinguishing hypothalamic from pituitary forms of idiopathic hypopituitary dwarfism. J Clin Invest 20:2219-2225, 1971.Crossref 8. Hershman JM, Pittman JA Jr: Utility of the radioimmunoassay of serum thyrotropin in man. Ann Intern Med 74:481-490, 1971.Crossref 9. Faglin G, et al: Prolonged and exaggerated elevations in plasma thyrotropin (HTSH) after releasing factor (TRF) in patients with pituitary tumors. J Clin Endocrinol Metab 33:999-1002, 1971.Crossref 10. Odell WD, Wilber JF, Paul WE: Radioimmunoassay of thyrotropin in human serum. J Clin Endocrinol Metab 25:1179-1188, 1965.Crossref 11. Patel YC, Burger HG, Hudson B: Radioimmunoassay of Serum Thyrotropin: Sensitivity and specificity. J Clin Endocrinol Metab 33:768-774,1971.Crossref 12. Greenwood FC, Hunter WM, Glover JS: The preparation of 131-I labeled human growth hormone of high specific radioactivity. Biochem J 89:114-123, 1963. 13. Samaan NA, et al: Serum placental lactogen levels during pregnancy and trophoblastic disease. J Clin Endocrinol Metab 26:1303-1308, 1966.Crossref 14. Morgan CR, Lazarow A: Immunoassay of insulin: Two antibody system: Plasma insulin levels of normal subdiabetic, and diabetic rats. Diabetes 12:115-126, 1963. 15. Murphy BEP: Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay. J Clin Endocrinol Metab 27:973-990, 1967.Crossref 16. Mitchell ML, Harden AB, O'Rourke ME: The in vitro resin sponge uptake of triiodothyronine 131I from serum in thyroid disease and in pregnancy. J Clin Endocrinol 20:1474-1483, 1960.Crossref 17. Murphy BEP, Pattee CJ: Determination of thyroxine utilizing the property of protein-binding. J Clin Endocrinol Metab 24:187-196, 1964.Crossref 18. Kennedy JA, Abelson DM: Determination of serum thyroxine using a resin sponge technique. J Clin Pathol 20:89-94, 1967.Crossref 19. Mikhail G, et al: Radioimmunoassay of plasma estrone and estradiol. Steroids 15:337-352, 1970.Crossref 20. Kato T, Horton R: A rapid method for the estimations of testosterone in female plasma. Steroids 12:631-650, 1968.Crossref 21. Peterson RE, et al: The physiological disposition and metabolic fate of hydrocortisone in man. J Clin Invest 34:1779-1794, 1955.Crossref 22. Snyder PJ, Utiger RD: Response to thyrotropin releasing hormone (TRH) in normal man. J Clin Endocrinol Metab 34:380-385, 1972.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Thyrotropin-Releasing Hormone as a Pituitary-Function Indicator: A Comparison With Other Tests

Loading next page...
 
/lp/american-medical-association/thyrotropin-releasing-hormone-as-a-pituitary-function-indicator-a-pu5KpYzAEc

References (25)

Publisher
American Medical Association
Copyright
Copyright © 1973 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1973.03650120044008
Publisher site
See Article on Publisher Site

Abstract

Abstract Pituitary thyrotropin reserves were tested with intravenous injections of 500μg of lopremone (synthetic thyrotropin-releasing hormone) in eight normal subjects, ten patients with complete hypopituitarism, and ten with incomplete hypopituitarism. Normal subjects had a mean basal thyrotropin-stimulating hormone level of 2.3μ± 1.8μU/ml and attained a mean maximal thyrotropin-stimulating hormone level of 19.8μ ± 8.2μU/ml 20 to 30 minutes after injection; no marked response occurred in patients with complete hypopituitarism. Of the incomplete hypopituitarism group, two had subnormal responses and were clinically hypothyroid. The others, clinically euthyroid, had normal responses compared to normal subjects of similar ages. Growth hormone reserve in this group was first to show impairment, whereas adrenocorticotropic hormone and thyrotropin-stimulating hormone reserves were last affected. The lopremone stimulation test is useful and specific in evaluating pituitary thyrotropin reserve. References 1. Hershman JM, Pittman JA Jr: Response to synthetic thyrotropin-releasing hormone in man. J Clin Endocrinol Metab 31:457-460, 1970.Crossref 2. Ormston BJ, et al: Further observations on the effect of synthetic thyrotropin-releasing hormone in man. Br Med J 2:199-202, 1971.Crossref 3. Anderson MS, et al: Synthetic thyrotropin-releasing hormone: A potent stimulator of thyrotropin secretion in man. N Engl J Med 285:1279-1283,1971.Crossref 4. Bowers CY, et al: Prolactin and thyrotropin release in man by synthetic pyroglutamyl-histidyl-prolinamide. Biochem Biophys Res Commun 45:1033-1041, 1971.Crossref 5. Fleisher N, et al: Preliminary observations on the effect of synthetic thyrotropin-releasing factor on plasma thyrotropin levels in man. J Clin Endocrinol Metab 31:109-112, 1970.Crossref 6. Haigler ED Jr, et al: Direct evaluation of pituitary thyrotropin releasing hormone. J Clin Endocrinol Metab 33:573-581, 1971.Crossref 7. Costom BH, Grumbach MM, Kaplan SL: Effect of thyrotropin-releasing factor on serum thyroid-stimulating hormone: An approach to distinguishing hypothalamic from pituitary forms of idiopathic hypopituitary dwarfism. J Clin Invest 20:2219-2225, 1971.Crossref 8. Hershman JM, Pittman JA Jr: Utility of the radioimmunoassay of serum thyrotropin in man. Ann Intern Med 74:481-490, 1971.Crossref 9. Faglin G, et al: Prolonged and exaggerated elevations in plasma thyrotropin (HTSH) after releasing factor (TRF) in patients with pituitary tumors. J Clin Endocrinol Metab 33:999-1002, 1971.Crossref 10. Odell WD, Wilber JF, Paul WE: Radioimmunoassay of thyrotropin in human serum. J Clin Endocrinol Metab 25:1179-1188, 1965.Crossref 11. Patel YC, Burger HG, Hudson B: Radioimmunoassay of Serum Thyrotropin: Sensitivity and specificity. J Clin Endocrinol Metab 33:768-774,1971.Crossref 12. Greenwood FC, Hunter WM, Glover JS: The preparation of 131-I labeled human growth hormone of high specific radioactivity. Biochem J 89:114-123, 1963. 13. Samaan NA, et al: Serum placental lactogen levels during pregnancy and trophoblastic disease. J Clin Endocrinol Metab 26:1303-1308, 1966.Crossref 14. Morgan CR, Lazarow A: Immunoassay of insulin: Two antibody system: Plasma insulin levels of normal subdiabetic, and diabetic rats. Diabetes 12:115-126, 1963. 15. Murphy BEP: Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay. J Clin Endocrinol Metab 27:973-990, 1967.Crossref 16. Mitchell ML, Harden AB, O'Rourke ME: The in vitro resin sponge uptake of triiodothyronine 131I from serum in thyroid disease and in pregnancy. J Clin Endocrinol 20:1474-1483, 1960.Crossref 17. Murphy BEP, Pattee CJ: Determination of thyroxine utilizing the property of protein-binding. J Clin Endocrinol Metab 24:187-196, 1964.Crossref 18. Kennedy JA, Abelson DM: Determination of serum thyroxine using a resin sponge technique. J Clin Pathol 20:89-94, 1967.Crossref 19. Mikhail G, et al: Radioimmunoassay of plasma estrone and estradiol. Steroids 15:337-352, 1970.Crossref 20. Kato T, Horton R: A rapid method for the estimations of testosterone in female plasma. Steroids 12:631-650, 1968.Crossref 21. Peterson RE, et al: The physiological disposition and metabolic fate of hydrocortisone in man. J Clin Invest 34:1779-1794, 1955.Crossref 22. Snyder PJ, Utiger RD: Response to thyrotropin releasing hormone (TRH) in normal man. J Clin Endocrinol Metab 34:380-385, 1972.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Dec 1, 1973

There are no references for this article.